Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;131(3):e171.
doi: 10.1213/ANE.0000000000005047.

In Response

Jonathan H Chow  1 , Michael A Mazzeffi  2 , Michael T McCurdy  3
Affiliations
Comment

In Response

Jonathan H Chow et al. Anesth Analg. 2020 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: J.H.C. serves on the Speaker’s Bureau for La Jolla Pharmaceutical Company.

Comment on

References

    1. Verdiner R. Is angiotensin II unopposed a good thing? Anesth Analg. 2020. - PMC - PubMed
    1. Chow JH, Mazzeffi MA, McCurdy MT. Angiotensin II for the treatment of COVID-19-related vasodilatory shock. Anesth Analg. 2020. - PMC - PubMed
    1. Ham KR, Boldt DW, McCurdy MT, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Ann Intensive Care. 2019;9:63. - PMC - PubMed
    1. Tumlin JA, Murugan R, Deane AM, et al. ; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46:949–957. - PMC - PubMed
    1. Bellomo R, Wunderink RG, Szerlip H, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care. 2020;24:43. - PMC - PubMed